| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
3 |
| Employees |
40 |
| Revenues (TTM) (Millions $) |
30 |
| Net Income (TTM) (Millions $) |
-55 |
| Cash Flow (TTM) (Millions $) |
-18 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Nabriva Therapeutics Plc is a biopharmaceutical company that develops and commercializes novel therapies to treat serious infections. The company is focused on the development of new antibiotics for the treatment of infections caused by drug-resistant bacteria.
Nabriva was founded in 2006 and is headquartered in Dublin, Ireland, with operations in the United States. The company is traded on the NASDAQ under the ticker symbol "NBRV."
The company's lead product is Xenleta (lefamulin), which is a first-in-class semi-synthetic pleuromutilin antibiotic for the treatment of community-acquired pneumonia (CAP). Xenleta is approved by the FDA in both intravenous (IV) and oral formulations for the treatment of CAP in adults. It is also approved in the European Union for the treatment of community-acquired pneumonia in adults.
In addition to Xenleta, Nabriva has a pipeline of antibacterial agents, including a second-generation pleuromutilin antibiotic for the treatment of acute bacterial skin and skin structure infections (ABSSSI), which is currently in Phase 3 clinical development.
Nabriva also has a research and development collaboration with the Chinese pharmaceutical company, Sinovant Sciences, focused on the development of new drugs to address the growing problem of bacterial resistance in China.
Overall, Nabriva is a clinical-stage biopharmaceutical company focused on the development of innovative antibiotics to combat serious infections caused by drug-resistant bacteria. The company is committed to creating new treatment options for healthcare providers and patients, and to helping address the global public health threat of antibiotic-resistant infections.
Company Address: 25-28 North Wall Quay Dublin 1 0
Company Phone Number: 649 2000 Stock Exchange / Ticker: NASDAQ NBRV
|
%
0.18%